Neurocrine Biosciences, Inc.
NBIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.43B
Close$
$491.16
200.6% upside
Current Fair Value
200.6% upsideUndervalued by 200.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.43 Billion |
|---|---|
| Enterprise Value | $16.83 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.81 |
| Beta | 0.39 |
| Outstanding Shares | 101,000,000 |
Return
| Return on Equity | 17.68% |
|---|---|
| Return on Assets | 13.16% |
| Return on Invested Capital | 17.56% |
Valuation & Multiples
| P/E Ratio | 23.18 |
|---|---|
| PEG | 67.53 |
| Price to Sales | 4.95 |
| Price to Book Ratio | 4.19 |
| Enterprise Value to Revenue | 4.99 |
| Enterprise Value to EBIT | 21.38 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$1.65
Average shareholder expectationRevenue Estimate
$891.16 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$2.59
Average shareholder expectationRevenue Estimate
$1.04 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 204.84% |
|---|---|
| Total Calls | 1,000▼ 99.51% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.39%▼ 95.08% |
|---|---|
| Total Invested | $736.26M▼ 94.40% |
| Investors Holding | 260▼ 454.00% |
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman